Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

20201,145 citationsJournal Articlebronze Open Access

Authors

Deepak L. Bhatt · Brigham and Women's Hospital

Michael Szarek · State University of New York

Bertram Pitt · University of Michigan

Christopher P. Cannon · Brigham and Women's Hospital

Lawrence A. Leiter · University of Toronto

Darren K. McGuire · Parkland Health & Hospital System

Julia B. Lewis

Abstract

In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).

Topics & Keywords

Diabetes Treatment and Management Pharmacology and Obesity Treatment Parkinson's Disease Mechanisms and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 2, pp. 129-139

DOI: 10.1056/nejmoa2030186

Field-Weighted Citation Impact: 101.74